$GILD Recent News Selling in growth-stock leaders

New Post Public Reply Private Reply Replies (0) Message Board

Nov 8, 2013 at 3:50 PM

$GILD Recent News

Selling in growth-stock leaders continues

11:23 a.m. Oct. 31, 2013

- The Trading Deck

LinkedIn, Yelp decline; Baidu rallies after hours

5:14 p.m. Oct. 29, 2013

- Wallace Witkowski

Gilead profit up 17% as HIV drugs top sales growth

4:07 p.m. Oct. 29, 2013

- MarketWatch.com

Gilead shares rise 1% in late trading

3:59 p.m. Oct. 29, 2013

- Laura Mandaro

Earnings season focus shifts to revenue, capex

8:53 a.m. Oct. 27, 2013

- Wallace Witkowski

Healthcare stocks fall from first place in race for year's best-performing sector

2:32 p.m. Oct. 24, 2013

- blogs.marketwatch.com

In focus: Overbought conditions abound

7:21 p.m. Oct. 23, 2013

- Lawrence G. McMillan

Best Buy tops S&P 500; Netflix snaps losing streak

3:21 p.m. Oct. 10, 2013

- Sue Chang

Best Buy, Gilead Sciences lead S&P 500 gainers

3:05 p.m. Oct. 10, 2013

- Polya Lesova

Gilead, Acura stand out on up day for stocks, Quest tumbles

10:27 a.m. Oct. 10, 2013

- Russ Britt

Gilead ends leukemia study after positive results

4:10 p.m. Oct. 9, 2013

- MarketWatch.com

Citrix, Ruby Tuesday shares fall after hours

4:06 p.m. Oct. 9, 2013

- Wallace Witkowski

10 popular health-care stocks among hedge funds

11:34 a.m. Sept. 4, 2013

- Insider Monkey

Charting a market divergence

10:21 a.m. Aug. 22, 2013

- Michael Ashbaugh

Earnings help McKesson, hospitals; FDA ruling hits Vertex, aids Gilead

9:52 a.m. July 26, 2013

- Russ Britt

S&P 500 up another 5% in 2013: J.P. Morgan's Thomas Lee

8:36 a.m. July 26, 2013

- blogs.marketwatch.com

Gilead soars on rival Vertex's drug-ruling misfortune

4:47 p.m. July 25, 2013

- Russ Britt

Updates, advisories and surprises

4:31 p.m. July 25, 2013

- MarketWatch

Gilead profit up 8.6% on sales growth of HIV drugs

3:37 p.m. July 25, 2013

- MarketWatch.com

Gilead profit rises, sales beat forecast

3:19 p.m. July 25, 2013

- Russ Britt

Gilead Vs. Challengers In The Hepatitis C Race

7:00 a.m. Nov. 7, 2013

- Seeking Alpha

Roche Pacing the Field in the Biotech Race

6:00 a.m. Nov. 6, 2013

- TheStreet.com

U.S. Launch of Actelion's Opsumit - Analyst Blog

4:30 p.m. Nov. 5, 2013

- Zacks.com

Ligand Pharmaceuticals On Pace For Annual Profit

4:25 p.m. Nov. 5, 2013

- Investors Business Daily

Analysts: Gilead Likely to Lead HCV Treatment and 3 More Research Notes to Read

11:25 a.m. Nov. 5, 2013

- Wall St. Cheat Sheet

Gilead Sciences Inc Continues With Buy Recommendation

9:00 a.m. Nov. 5, 2013

- TheStreet.com

UBS Adds Six Top Alpha Preference List Stocks to Buy for 2014

7:34 a.m. Nov. 5, 2013

- 247WallSt.com

Stock Splits Rekindle a Polarizing Debate

8:44 p.m. Nov. 4, 2013

- WSJ.com

Top-Performing Mutual Funds Like Facebook

5:01 p.m. Nov. 4, 2013

- Investors Business Daily

Bristol-Myers Seeks Japanese Approval - Analyst Blog

2:30 p.m. Nov. 4, 2013

- Zacks.com

Protect Your Investments Against a Bubble, Know What Makes a Bubble

10:28 a.m. Nov. 4, 2013

- TheStreet.com

Benzinga's Top #PreMarket Losers

7:37 a.m. Nov. 4, 2013

- benzinga.com

Invest In Gilead Sciences For Long-Term Hepatitis C Franchise

2:13 a.m. Nov. 4, 2013

- Seeking Alpha

Gilead Announces Positive Phase 3 HCV Treatment Results in Patients Co-Infected With HIV

4:15 p.m. Nov. 2, 2013

- benzinga.com

Gilead Announces Promising Phase 2 HCV Treatment Results in Liver Transplant Patients

4:12 p.m. Nov. 2, 2013

- benzinga.com

Why Idenix Could Rise Even Higher, and Challenge Gilead and Vertex

6:40 a.m. Nov. 2, 2013

- 247WallSt.com

Jim Cramer's 6 Stocks in 60 Seconds: VRTX GTLS YELP AVD Q GRPN (Update 1)

5:20 p.m. Nov. 1, 2013

- TheStreet.com

Argus' Market Digest Summary

9:47 a.m. Nov. 1, 2013

- benzinga.com

Top Analyst Upgrades and Downgrades: Facebook, Netflix, PetSmart, Valero and More

7:54 a.m. Nov. 1, 2013

- 247WallSt.com

Bull of the Day: Pharmacyclics (PCYC) - Bull of the Day

4:15 a.m. Oct. 31, 2013

- Zacks.com

S.F. Voters Repudiate Gilead, Other Pharma's Greed with Prop. D Victory

7:47 p.m. Nov. 7, 2013

- BusinessWire

Gilead to Present Data on Oncology Pipeline at American Society of Hematology Annual Meeting

9:00 a.m. Nov. 7, 2013

- BusinessWire

Clinical Trial Data, New Publications, Promotions, Financial Results and FDA Acknowledgements - Research Report on Gilead, Amgen, ACADIA Pharmaceuticals, ViroPharma, and MannKind

8:00 a.m. Nov. 6, 2013

- PR Newswire

Under AAAResearchReports.com Microscope: Gilead Sciences Inc., NPS Pharma Inc., Halozyme Therapeutics Inc., and InterMune Inc.

11:14 a.m. Nov. 4, 2013

- PR Newswire

Quarterly Financial Reports, Clinical Study Results, and R&D Events for the Investment Community - Research Report on Gilead Sciences, Clovis, Theravance, Charles River, and Acorda

8:00 a.m. Nov. 4, 2013

- PR Newswire

Gilead Announces New Sustained Viral Response Data for Sofosbuvir-Based Regimens in Genotype 3-Infected Hepatitis C Patients

9:01 a.m. Nov. 2, 2013

- BusinessWire

Gilead Announces Phase 3 Results for an All-Oral, Sofosbuvir-Based Regimen for the Treatment of Hepatitis C in Patients Co-Infected With HIV

9:01 a.m. Nov. 2, 2013

- BusinessWire

Gilead Announces Phase 2 Results for Sofosbuvir-Based Regimens in Hepatitis C Patients Before and After Liver Transplantation

9:01 a.m. Nov. 2, 2013

- BusinessWire

Dun & Bradstreet CEO Sara Mathew Named Top S&P 500 Wealth Creator in 2013

8:30 a.m. Oct. 31, 2013

- PR Newswire

Sector Leaders Briefing & Capital Raise News: Muscle Warfare, Baidu, Herblife, Gilead Sciences and ARIAD

9:08 a.m. Oct. 30, 2013

- PR Newswire

Gilead Sciences Announces Third Quarter 2013 Financial Results

4:02 p.m. Oct. 29, 2013

- BusinessWire

Critical Alerts For Gilead Sciences, Trina Solar, T Rowe Price, Suncor Energy, and Morgan Stanley Released By InvestorsObserver

9:31 a.m. Oct. 29, 2013

- PR Newswire

The Non-Hodgkin's Lymphoma Drug Market Will Nearly Double to More Than $10 Billion by 2022

9:00 a.m. Oct. 28, 2013

- PR Newswire

FDA Advisory Committee Supports Approval of Gilead's Sofosbuvir for Chronic Hepatitis C Infection

4:43 p.m. Oct. 25, 2013

- BusinessWire

Gilead Sciences to Release Third Quarter 2013 Financial Results on Tuesday, October 29, 2013

5:00 p.m. Oct. 22, 2013

- BusinessWire

Stock Price Movements, Clinical Study Results, and New Appointments - Research Report on Pfizer, Gilead Sciences, Amgen, Celgene, and Insys Therapeutics

8:00 a.m. Oct. 22, 2013

- PR Newswire

Innovative Biotechs Making Strides In Healthcare Sector: Alliqua, MiMedx, Organovo, Anacor Pharmaceuticals, Pfizer

9:05 a.m. Oct. 21, 2013

- PR Newswire

Insider Trading Tips for Google, Rite Aid, American Express, Advanced Micro Devices, J.C. Penney, and Ariad Pharmaceuticals

8:55 a.m. Oct. 21, 2013

- PR Newswire

Gilead's Single Tablet HIV Regimen Stribild(R) Demonstrates Durable Viral Suppression Through Three Years of Therapy

3:10 a.m. Oct. 16, 2013

- BusinessWire

GlobeImmune Announces Milestone Payment for Initiation of Phase 2 Clinical Trial for GS-4774 (Formerly GI-13020) in Patients with Chronic Hepatitis B Virus Infection

7:00 a.m. Oct. 15, 2013

- Thomson Reuters ONE

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Pizza: The Unlikely Symbol of Universal Togetherness

Why Pizza Is More Than Just Food They say a slice of pizza can tell a story. Whether it's a late-night snack amongst college buddies or the centerpiece of a family's Friday tradition, pizza unites like few others can. It morphs from a study aid into a tool for togetherness without skipping a beat, much like a chameleon of the food world. And no one understands this better...

Damp or Dry: The Battle for Healthy Air in Colorado

The Hidden Cost of Colorado's Dry Air Dry climate isn't just a seasonal inconvenience—it's a real hidden cost to living comfortably and healthily in Colorado. With winters colder than a brass monkey's tail and summers that don't offer much relief in terms of humidity, your home's air quality is on the front line. So, what's the financial tale here, and how do you come...

Protecting Teeth: Insights from Endodontist Dr. Joubert

Preserving Our Natural Chompers Digging into the details of endodontic care, you realize how it's the unsung hero in the dental world. And let's face it, teeth don't get happier on their own when there's a problem on the inside. Dr. Christopher Joubert, a wiz on the endodontic front, spills the beans over at HelloNation about how essential these practices are in keeping...

Countries Eye New Investment Paths at CIFIT 2026

Global Investment Winds Shift at CIFIT In the thick of a world that's being turned on its head, you've got big shots from 129 countries and 30 international organizations talking shop at the 26th China International Fair for Investment and Trade (CIFIT) in Xiamen. Take your pick from the 48 of the world's top 50 GDP powerhouses rubbing shoulders there—this ain't your...

New 2027 Jeep Wrangler JL-2A: A Blast from the Past

Revisiting a Prized Legacy: The 2027 Jeep Wrangler JL-2A Sometimes, what’s new is really just a nod to what’s old—and nowhere is this more so than with the 2027 Jeep Wrangler JL-2A. In the grand parade of automotive history, Jeep's latest creation is more than just a vehicle; it's a time machine that cruises on its historic lineage while strapping on all the modern...

D-Wave Faces Legal Questions After CFO Exit and Losses

Trouble Brews at D-Wave Quantum Smack in the middle of market chaos, D-Wave Quantum Inc. (NASDAQ: QBTS) seems to have hit a rather gnarly pothole. With disappointing revenue figures for Q2 of 2026—coming in at a measly $3.08 million, far below the expected range of $4.03 million to $4.08 million—investors have more than enough reasons to be irked. When the numbers...

PureHealth's Acid Reflux Solutions: An Investor's Insight

Digestive Wellness: The Emerging Opportunity Some days, it feels like everybody's got a gripe about their gut. You nod along at the lunch counter, folks buzzing about digestive this and acid that. But when PureHealth Research pops up with their fancy supplements, well, even the stock market's noisier nonsense starts sounding a bit quieter. They're banking big on the...

ARTiSTORY's Strategic Advance in Cultural IP Licensing

Call it a seismic shift or call it common sense, but ARTiSTORY's recent haul of accolades makes it clear: they're onto something big in the cultural IP game. Receiving four honors at the 26th International Advertising Institute Awards (IAI Awards), including a Gold for their British Library × CHAGEE collaboration, and jumping into License Global's Top 60, they're staking...

Larry Ellison's Moves Signal Confidence in Oracle's Future

Unraveling Ellison's Bold Decision There's nothing like a sudden shift from a tech titan to make Wall Street sit up and take notice. Today, we got the word that Larry Ellison, Oracle's big gun as Executive Chair and CTO, has pulled the plug on his plan to sell Oracle stock. No dice, no distance covered under that plan. And he's made it crystal clear—selling isn't on his...

SystImmune's Data on Iza-bren Show Promise for Lung Cancer

Stepping into New Territory with SystImmune Amid the cacophony of biotech whispers and the marketplace hum, SystImmune is trotting out something that might just make the folks in lab coats raise an eyebrow. They’ve got new data for Iza-bren—none of that flashy PR chatter—but it's damn promising if you ask me. At the World Conference on Lung Cancer in Seoul,...